FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as "anticipate," "believe," "estimate," "intend," "could," "should," "would," "may," "seek," "plan," "might," "will," "expect," "predict," "project," "forecast," "potential," "continue" negatives thereof or similar expressions. Forward-looking statements contained in this report speak only as of the date of this report, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, matters associated with:





       ·    our ability to continue as a going concern,
       ·    our history of losses which we expect to continue,
       ·    the significant amount of liabilities due to related parties,
       ·    our ability to raise sufficient capital to fund our company,
       ·    our ability to integrate acquisitions and the operations of acquired
            companies,
       ·    the limited experience of our management in the operations of a public
            company,
       ·    potential weaknesses in our internal control over financial reporting,
       ·    increased costs associated with reporting obligations as a public
            company,
       ·    a limited market for our common stock and limitations resulting from
            our common stock being designated as a penny stock,
       ·    the ability of our board of directors to issue preferred stock without
            the consent of our stockholders,
       ·    our management controls the voting of our outstanding securities,
       ·    the conversion of shares of Series A and B preferred stock will be
            very dilutive to our existing common stockholders,
       ·    risks associated with and unique to health care, and
       ·    risks associated with stability of the internet, data security,
            exposure to data breach.



You should read thoroughly this report and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements, including those made in this report, in Part I. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. Other sections of this report include additional factors which could adversely impact our business and financial performance. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. These forward-looking statements speak only as of the date of this report, and you should not rely on these statements without also considering the risks and uncertainties associated with these statements and our business.





                          OTHER PERTINENT INFORMATION


Unless specifically set forth to the contrary, when used in this report the terms "MediXall Group", the "Company," "we", "us", "our" and similar terms refer to MediXall Group, Inc., a Nevada corporation, and its wholly-owned subsidiaries.





GENERAL


The following Management's Discussion and Analysis ("MD&A") is intended to help the reader understand the Company's results of operations and financial condition. The MD&A is provided as a supplement to, and should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in this Quarterly Report on Form 10-Q.





12






The MD&A is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.





OVERVIEW


MediXall Group, Inc. (OTCQB:MDXL) is an innovation-driven technology company purposefully designed and structured around delivering products and services to help consumers learn, decide, and pay for healthcare in ways that complement relationships with trusted doctors. The mission of MediXall Group is to revolutionize the medical industry--improve communication, provide better technology and support services, and provide more efficient, cost-effective healthcare for the consumer.





Going Concern


We have incurred net losses of approximately $30.8 million since inception through September 30, 2022. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2021 contains an explanatory paragraph regarding our ability to continue as a going concern based upon the fact that we are dependent upon our ability to increase revenues along with raising additional external capital as needed. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate revenues or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company.





Results of Operations



Three Month Period Ended September 30, 2022 Compared to the Three Month Period Ended September 30, 2021





Revenue


We had nominal revenue for the three months ended September 30, 2022 and 2021.





Operating Expenses



A summary of our operating expense for the three month periods ended September
30, 2022 and 2021 follows:



                                                      Three Months Ended
                                                         September 30,             (Decrease) /
                                                     2022            2021            Increase
Operating expense
Professional fees                                 $   227,914     $   323,316     $      (95,402 )
Professional fees - related party                      50,100          40,000             10,100
Management fee - related party                        240,000         240,000                  -
Personnel related expenses                            273,120         533,130           (260,010 )
Other selling, general, and administrative            313,510         258,498             55,012
Total operating expense                           $ 1,104,644     $ 1,394,944     $     (290,300 )




13






Operating expenses decreased $290,300, or 21%, to $1,104,644 during the three months ended September 30, 2022 compared to $1,394,944 during the same period in 2021. The decrease in total operating expenses is primarily due to:





       1.   The decrease in professional fees of $95,402 primarily resulted from
            the Company issuing fewer shares of its restricted common stock for
            consulting services during the three month period ended September 30,
            2022 compared the three month period ended September 30, 2021.




       2.   The increase in professional fees - related party of 10,100 is
            primarily due to an increase R3 service fees for the three months
            ended period September 30, 2022 compared to the three months ended
            period September 30, 2021.




       3.   The decrease in personnel related expenses of $260,010 is due to a
            decrease of payroll costs during the three month period ended
            September 30, 2022 compared to September 30, 2021.




       4.   The increase of $55,012 in other selling, general, and administrative
            is due to a increase in business development and marketing expenses
            during the three month period ended September 30, 2022.



We expect expenses to increase as we move forward with further enhancing the platform.

Nine Month Period Ended September 30, 2022 Compared to the Nine Month Period Ended September 30, 2021





Revenue


We had nominal revenue for the nine months ended September 30, 2022 and 2021. The revenue in 2021, was mainly from Paycheck Protection Program loan forgiveness.





Operating Expenses



A summary of our operating expense for the nine month periods ended September
30, 2022 and 2021 follows:



                                                       Nine Months Ended
                                                         September 30,             (Decrease) /
                                                     2022            2021            Increase
Operating expense
Professional fees                                 $   824,527     $ 1,004,976     $     (180,449 )
Professional fees - related party                     227,600         451,038           (223,438 )
Management fee - related party                        720,000         600,000            120,000
Personnel related expenses                          2,587,035       1,817,042            769,993
Other selling, general, and administrative            727,837         683,318             44,519
Total operating expense                           $ 5,086,999     $ 4,556,374     $      530,625

Operating expenses increase $530,625 or 12%, to $5,086,999 during the nine months ended September 30, 2022 compared to $4,556,374 during the same period in 2021. The increase in total operating expenses is primarily due to:

1. The decrease in professional fees of $180,449 primarily resulted from the


    Company issuing fewer shares of restricted common stock for consulting
    services during the nine month period ended September 30, 2022 compared to the
    nine month period ended September 30, 2021.



2. The decrease in Professional fees - related party of $223,438 is primarily due


    to a decrease in marketing and consulting expenses from a related party,
    partially offset by an increase in R3 service fees for the nine months period
    ended September 30, 2022.



3. The increase in management fees - related party of $120,000 is due to an

additional contract entered into with TBG to provide management services to

our wholly-owned subsidiary, Health Karma, Inc during the nine month period

ended September 30, 2022. There was no such contract during the nine month

period ended September 30, 2021.






14






4. The increase in personnel related expenses of $769,993 is due to more


    personnel needed for business operations and issuing shares of restricted
    common stock for employee services during the nine month period ended
    September 30, 2022, in excess of that issued in the same period 2021.



5. The increase of $44,519 in other selling, general, and administrative is due

to an increase in business development and marketing expenses during the nine

month period ended September 30, 2022.

We expect expenses to increase as we move forward with further enhancing the platform.

Liquidity and capital resources

Liquidity is the ability of a company to generate sufficient cash to satisfy its needs. At September 30, 2022, we had $75,578 in cash and a net working capital deficit of $3,596,089.

For the nine month period ended September 30, 2022, we raised $760,500 and $2,214,462 from sales of our restricted common stock and issuance of convertible debt, respectively. For the nine month period ended September 30, 2021, we raised $3,407,766 from sales of our restricted common stock and preferred stock.

Net cash used in operating activities for nine month period ended September 30, 2022 was $2,962,802, as compared to $3,690,310 for the nine month period ended September 30, 2021. This change primarily results from our increased net loss, offset by fluctuations in accounts payable and accrued expenses, accounts payable and accrued expenses-related party and the issuance of common stock for services rendered.

Our primary source of capital to develop and implement our business plan has been from sales of common, preferred stock and proceeds from convertible debentures.

Other Contractual Obligations





None.


Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.





Critical Accounting Policies



Use of Estimates


The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustment is reflected in current operations.





15







Risks and Uncertainties



The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure.

Share Based Payment Arrangements

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company fair values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

Recoverability of Long-Lived Assets

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the nine month periods ended September 30, 2022 and 2021. However, there can be no assurances that future impairment tests will not result in a charge to operations.

Rights-to-use Intellectual Property

The rights-to-use intellectual property ("Intellectual Property") is an intangible asset arising from the Company's right to use the proprietary technology and programs of the Virtual Clinic. The Intellectual Property was initially measured at fair value and will be amortized on a straightline basis over its estimated useful life as the economic benefits are consumed or otherwise realized. Management has determined the estimated useful life to be seven years.

Website and Development Costs

Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of September 30, 2022 and December 31, 2021, the Company has met the capitalization requirements, and then began to amortize the assets. Amortization is calculated using the straight line method over the estimated useful life of the assets, which management determined to be five years.

© Edgar Online, source Glimpses